This series of bite-sized episodes will provide information about the cardiometabolic risk and potential for weight gain faced by patients with HIV. Tune in to hear Drs. Sorana Segal-Maurer, David Wohl, and Carl Fichtenbaum discuss the guidelines, strategies, data, and adverse events you need to be aware of to provide the best care for your patients.
HIV and Cardiometabolic Health: What's the Connection?
HIV and Cardiometabolic Health: What's the Connection?
Welcome to CME on ReachMD. This episode is part of our MinuteCE curriculum.
Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.
This is CME on ReachMD, and I’m Dr. Sorana Segal-Maurer. Here with me today is Dr. David Wohl.
So, Dr. Wohl, let’s dive right in. Are people living with HIV at increased cardiometabolic risk?
The short answer is yes, but it’s not a full stop because we do know that people living with HIV are at a higher risk – if you had a bunch of people living with HIV and a bunch of people not living with HIV, chances are if you followed them, more cardiovascular disease in the folks living with HIV. The more complicated issue is why? And what is driving that? And as you know, there’s a lot of factors that play into cardiovascular risk, including a lot of the traditional risk factors, but also things we’re worried about that have to do with HIV.
So very interesting points. Do you think that people living with HIV, living longer now than decades ago, does that impact our cardiometabolic risk in our people living with HIV?
Of course, for sure. If you’re not dying from toxoplasma encephalitis or PJP [pneumocystis jiroveci pneumonia], you’re living a longer life. And I tell my patients all the time, you know, my goal is to have you live long enough to get old enough to have a heart attack, a stroke, or cancer. Because that’s what kills the rest of us, most of the rest of us. So I think, really, it’s a complicated issue in that it’s very hard, as you know, to compare people living with HIV to some comparator group. It’s been very challenging to do that. And even in cohorts where people are – like the MACS cohort or the WIHS cohort – where people living with HIV are enrolled and so are people at risk for HIV, even then, we don’t see exact parity. So my big thing – and I think a lot of us who have observed this – is there are so many traditional risk factors that are enriched for in people living with HIV, whether it be smoking. So again, if we take a group of people with HIV, people without HIV, and look at rates of heart attacks, higher in the HIV group – but so is smoking, or a history of smoking. And not only that, but there’s other risk factors that we have to really worry about that may be less obvious like substance use. And we don’t know the contribution of vaping or smoking marijuana or even crack cocaine or other types of cocaine. And there’s a lot of data showing that some of the MIs [myocardial infarctions] that people are experiencing with HIV are disproportionately related to issues with demand and delivery and supply of blood. So it’s not so much atherosclerosis, but maybe some of this more type 2 MI that may be facilitated by vasoconstrictors like cocaine or methamphetamines. So it’s complicated.
My feeling, to be honest, is that the vast majority of cardiovascular disease in people living with HIV is due to traditional risk factors and some of the traditional risk factors that we don’t appreciate, like stress, poverty, food insecurity. We do know that adverse childhood experiences – we do know that these things also contribute to poor outcomes in people, including cardiovascular disease. So it’s very hard to compare apples with apples, but that doesn’t mean that there isn’t something going on vis-à-vis inflammation with HIV or medications as well.
That’s right. So we will dive into that with another episode in terms of antiretroviral agents. You bring up a couple of very important points, which I think we will explore further in future episodes: the traditional risk factors, in addition to some HIV-specific risk factors. One thing that I think bears repeating is our patients are living longer, number one. As they age, they’re going to have more comorbid conditions, and there are actually estimates in some of the very large cohorts, the NA ACCORD [The North American AIDS Cohort Collaboration on Research and Design] cohort, that tell us over the next several decades, we’re going to be dealing with many more comorbid conditions in our people living with HIV. The other thing that you brought up, which is very stimulating to me, is that our HIV epidemic really intersects a number of other epidemics, certainly in the US, such as obesity and other cardiometabolic events. We will delve more into all of this with future episodes.
For today, this has been a great bite-sized discussion, Dr. Wohl. More to be said. That’s all our time, everyone. Thanks so much for listening.
You have been listening to CME on ReachMD. This activity is provided by Prova Education and is part of our MinuteCE curriculum.
To receive your free CME credit, or to download this activity, go to ReachMD.com/Prova. Thank you for listening.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Sorana Segal-Maurer, MD
Director, The Dr. James J. Rahal Jr. Division of Infectious Diseases
Professor of Clinical Medicine
Weill Cornell Medical College, Cornell University
New York, NY
Consulting Fees: Gilead, Janssen, ViiV Healthcare
Carl J. Fichtenbaum, MD
Gregory W. Rouan Professor of Internal Medicine
University of Cincinnati
Research: Gilead Sciences, Merck & Co., Inc., ViiV Healthcare
Consulting Fees: Theratechnologies, ViiV Healthcare
David Wohl, MD
Professor of Medicine
The University of North Carolina at Chapel Hill
Chapel Hill, NC
Research: Gilead, Merck & Co., Inc., ViiV Healthcare
Consulting Fees: Gilead, Janssen, Theratechnologies, ViiV Healthcare
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Keith Johnson has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Tim Person has nothing to disclose.
- Rosanne Strauss, PharmD, MBA, has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Assess cardiometabolic risk factors in patients with HIV receiving antiretroviral therapy (ART) at regular intervals
- Select antiretroviral (ARV) regimens to help protect cardiometabolic health in patients with HIV at known increased risk
- Identify benefits of some non-nucleoside reverse transcriptase inhibitors (NNRTIs) when there is a need to avoid or switch from integrase strand transfer inhibitor (INSTI)-based ARV regimens
This activity is designed to meet the educational needs of infectious disease physicians, primary care physicians, and infectious disease nurses and physician assistants.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 8/21/2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Merck & Co., Inc.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.